UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S571-S572

2024

Volltextzugriff (PDF)

Precision medicine for multiple myeloma: The case for translocation (11;14)

Cancer treatment reviews, 2024-11, Vol.130, p.102823, Article 102823

2024

Volltextzugriff (PDF)

MiR-27a inhibits the growth and metastasis of multiple myeloma through regulating Th17/Treg balance

PloS one, 2024-10, Vol.19 (10), p.e0311419

2024

Volltextzugriff (PDF)

Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma

Frontiers in immunology, 2024-09, Vol.15, p.1469794

2024

Volltextzugriff (PDF)

Leveraging diverse cellular stress patterns for predicting clinical outcomes and therapeutic responses in patients with multiple myeloma

Journal of cellular and molecular medicine, 2024-09, Vol.28 (17), p.e70054

2024

Volltextzugriff (PDF)

Research Progress on Ferroptosis in Multiple Myeloma

Current treatment options in oncology, 2024-10, Vol.25 (10), p.1276-1282

2024

Volltextzugriff (PDF)

Bispecific antibody targets and therapies in multiple myeloma

Frontiers in immunology, 2024-10, Vol.15, p.1424925

2024

Volltextzugriff (PDF)

Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma

International journal of molecular sciences, 2024-08, Vol.25 (16), p.9022

2024

Volltextzugriff (PDF)

Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon

Cellular and molecular life sciences : CMLS, 2024-12, Vol.81 (1), p.349, Article 349

2024

Volltextzugriff (PDF)

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Blood cancer journal (New York), 2024-08, Vol.14 (1), p.149-10

2024

Volltextzugriff (PDF)

Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells

Oncogene, 2024-09, Vol.43 (40), p.3019-3019

2024

Volltextzugriff (PDF)

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

Hematology (Luxembourg), 2024-12, Vol.29 (1), p.2399430

2024

Volltextzugriff (PDF)

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma

Nature communications, 2024-08, Vol.15 (1), p.6810-21, Article 6810

2024

Volltextzugriff (PDF)

Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization

Lipids in health and disease, 2024-09, Vol.23 (1), p.299-11, Article 299

2024

Volltextzugriff (PDF)

Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma

Molecular biology reports, 2024-12, Vol.51 (1), p.972, Article 972

2024

Volltextzugriff (PDF)

Improving Health Outcomes Through Treatment Sequencing Optimization in Multiple Myeloma: A Simulation Model in Transplant‐Ineligible Patients

Cancer reports, 2024-10, Vol.7 (10), p.e70027-n/a

2024

Volltextzugriff (PDF)

Targeting GPRC5D for multiple myeloma therapy

Journal of hematology and oncology, 2024-09, Vol.17 (1), p.88-19, Article 88

2024

Volltextzugriff (PDF)

Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Oncogene, 2024-09, Vol.43 (40), p.3018-3018

2024

Volltextzugriff (PDF)

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

Blood cancer journal (New York), 2024-08, Vol.14 (1), p.138-12

2024

Volltextzugriff (PDF)

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis

PloS one, 2024-09, Vol.19 (9), p.e0308463

2024

Volltextzugriff (PDF)

An automated network-based tool to search for metabolic vulnerabilities in cancer

Nature communications, 2024-10, Vol.15 (1), p.8685-15, Article 8685

2024

Volltextzugriff (PDF)

Construction and validation of a prognostic model of angiogenesis-related genes in multiple myeloma

BMC cancer, 2024-10, Vol.24 (1), p.1269-15, Article 1269

2024

Volltextzugriff (PDF)

Bispecific antibodies in the treatment of multiple myeloma

Blood cancer journal (New York), 2024-09, Vol.14 (1), p.158-17, Article 158

2024

Volltextzugriff (PDF)

Prognosis and immune biomarkers of multiple myeloma

Xi bao yu fen zi mian yi xue za zhi, 2024-07, Vol.40 (7), p.642

2024

Volltextzugriff (PDF)

Current status of BAFF targeting immunotherapy in B-cell neoplasm

International journal of clinical oncology, 2024-11, Vol.29 (11), p.1676-1683

2024

Volltextzugriff (PDF)

1 – 25 von 658

Suche als RSS-Feed

Aktive Filter

ThemaMale

Neu hinzugefügt... seit 90 Tagen

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(378)
Mit Volltextzugriff
(459)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(6)
... seit 30 Tagen
(109)

Menü

Weitere Dienste

Einstellungen

MM-559 Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review

Precision medicine for multiple myeloma: The case for translocation (11;14)

MiR-27a inhibits the growth and metastasis of multiple myeloma through regulating Th17/Treg balance

Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma

Leveraging diverse cellular stress patterns for predicting clinical outcomes and therapeutic responses in patients with multiple myeloma

Research Progress on Ferroptosis in Multiple Myeloma

Bispecific antibody targets and therapies in multiple myeloma

Molecular Signatures of CB-6644 Inhibition of the RUVBL1/2 Complex in Multiple Myeloma

Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma

Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization

Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma

Improving Health Outcomes Through Treatment Sequencing Optimization in Multiple Myeloma: A Simulation Model in Transplant‐Ineligible Patients

Targeting GPRC5D for multiple myeloma therapy

Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis

An automated network-based tool to search for metabolic vulnerabilities in cancer

Construction and validation of a prognostic model of angiogenesis-related genes in multiple myeloma

Bispecific antibodies in the treatment of multiple myeloma

Prognosis and immune biomarkers of multiple myeloma

Current status of BAFF targeting immunotherapy in B-cell neoplasm

Aktive Filter

Suchergebnisse filtern